Arcturus Strengthens Pipeline as Key Phase 2 Milestones Approach and KOSTAIVE® Rights Return

Pipeline Progress: ARCT-032 and ARCT-810 Advance Toward Major Late 2026 Decisions

Arcturus Therapeutics is making notable progress in its rare disease and vaccine programs, highlighted by on-schedule enrollment in its Phase 2 study for ARCT-032, a cystic fibrosis mRNA therapy. The company expects a decision on advancing ARCT-032 into Phase 3 late in 2026, a key moment that could unlock further support through its collaboration with Thermo Fisher Scientific.

Meanwhile, ARCT-810—targeting ornithine transcarbamylase (OTC) deficiency—has completed dosing for all its Phase 2 trial participants. Arcturus plans to share fresh data and the next phase of its regulatory strategy for ARCT-810 by the end of Q3 2026. These developments underscore the company’s disciplined focus on its highest-priority clinical programs in mRNA-based rare disease therapeutics.

Strategic Collaboration and Portfolio Reshaping Bring Financial Flexibility

One standout from this quarter: Arcturus regained global rights to KOSTAIVE®—the first self-amplifying mRNA COVID vaccine to receive approval—and its broader infectious disease portfolio after resolving a partnership with CSL Seqirus. As part of the agreement, Arcturus receives a one-time $12 million cash payment and $16 million in released liabilities and R&D credits, immediately strengthening its balance sheet. The company now evaluates fresh commercial and partnering possibilities for the vaccine platform, aiming to maximize its future value.

Thermo Fisher Scientific’s partnership adds further stability, providing phase 3 manufacturing and related support for cystic fibrosis therapies, setting a clearer path to late-stage development pending Phase 2 trial outcomes.

Financial Snapshot: Cash Runway Extends Beyond 2028 Despite Quarterly Losses

While revenue fell this quarter versus last year, mainly due to the wind-down of the CSL Seqirus collaboration, R&D expenses also dropped significantly as Arcturus tightened its focus. The company maintains a strong cash position, reporting over $191 million in cash and equivalents as of June 30, 2026, with management confident in their runway of more than two and a half years, extending through year-end 2028.

General and administrative expenses were largely stable year-over-year, while net losses widened due to lower recognized revenue. Despite the shortfall, management highlights a "strong balance sheet" as the company realigns its strategic priorities and prepares for upcoming trial milestones.

Broader Strategy: Entering a New Chapter With Reclaimed Vaccine Rights and Late-Stage Trials

With regaining global rights to KOSTAIVE® and its infectious disease pipeline, Arcturus now has an open field to maximize upside through new development, commercial partnerships, or licensing moves. The anticipated Phase 3 decision for ARCT-032 in late 2026 could be the next value-trigger, especially with Thermo Fisher’s backing providing manufacturing and research muscle.

For investors and industry watchers, the key events to monitor over the next several quarters will be:

• The data and regulatory plan for ARCT-810 (OTC deficiency), likely due by Q3 2026.
• The decision on Phase 3 advancement for ARCT-032 (cystic fibrosis) anticipated by Q4 2026.
• Any new commercial, development, or partnership announcements related to KOSTAIVE® or the sa-mRNA infectious disease vaccine portfolio.

Arcturus appears well-positioned for potential inflection points in its clinical pipeline and strategic portfolio, despite swings in revenue and persistent net losses. With a significant cash buffer and tighter capital discipline, the company is set up for pivotal data releases and development decisions in late 2026.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI